精神病學數位生物標記市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、臨床實踐、最終用戶、地區和競爭格局分類，2021-2031年）

全球精神疾病數位生物標記市場預計將從 2025 年的 7.8698 億美元大幅成長至 2031 年的 22.6202 億美元，複合年成長率達 19.24%。

這些生物標記是客觀、可量化的生理和行為數據，透過智慧型手機和穿戴式裝置等數位平台收集，用於檢測和監測精神疾病。其主要成長要素包括：迫切需要客觀的臨床評估工具來補充患者主觀報告的數據，以及在患者照護和藥物研發中對可擴展遠端監測日益成長的需求。根據數位醫學協會2024年預測，在3期臨床試驗中應用數位化終點，預計每個適應症的淨現值（NPV）可提高高達4000萬美元，凸顯了採用這些創新技術的製藥開發商可獲得的盈利投資回報（ROI）。

儘管存在這些強勁的商業性促進因素，但市場仍面臨與資料隱私和複雜監管相關的重大障礙。收集高度敏感的心理健康資訊引發了關於患者知情同意、資料安全以及演算法偏見風險的嚴重倫理問題。這些隱私挑戰導致法規環境碎片化，使全球合規變得更加複雜，並有可能削弱患者信任，最終減緩這些數位化解決方案在臨床環境中的廣泛應用。

市場促進因素

精神疾病盛行率的不斷上升是推動精神疾病數位生物標記應用的重要基礎性因素，它將焦點從純粹的主觀報告轉向客觀、可擴展的診斷工具。隨著全球焦慮和憂鬱症負擔的加重，醫療保健系統越來越依賴數位表現型分析來高效管理龐大的患者群體。近期統計數據凸顯了這項迫切需求。 2024年7月，美國藥物濫用和精神健康服務管理局（SAMHSA）在2023年全國藥物使用與健康調查中報告稱，約有22.8%的美國成年人在過去一年中患有精神疾病。日益加重的疾病負擔迫切需要能夠實現持續遠端監測的數位工具，以便及早發現行為和生理異常並及時介入。

同時，對數位心理健康技術的投資浪潮正迅速提升這些生物標記的臨床有效性和技術水平。新創公司和製藥公司正積極投資於精準精神病學平台，利用機器學習進行患者分層和治療最佳化。 Alto Neurosciences 就是充分體現市場信心的典型例子，該公司在 2024 年 2 月的首次股票公開發行(IPO) 中籌集了約 1.286 億美元（請參閱「Alto Neurosciences 公佈首次股票公開發行定價」）。這些資金將用於開發基於生物標記的精神疾病治療方法。消費硬體領域的監管成功推動了這項資金籌措勢頭。例如，三星電子於 2024 年獲得了 FDA 的全新睡眠呼吸中止症檢測產品批准，這證實了消費級感測器在神經和精神監測方面的臨床應用價值。

市場挑戰

資料隱私問題和監管複雜性正對全球精神病學數位生物標記市場施加巨大壓力，削弱了臨床應用所需的信任。由於這些生物標記依賴於對高度敏感的行為和生理數據的持續追蹤，數據管治的模糊性導致醫療服務提供者和患者都產生了強烈的抵觸情緒。此外，不同司法管轄區法規結構的碎片化增加了合規成本，延緩了市場准入，有效地阻礙了可擴展遠端監測技術的應用。缺乏統一明確的標準引發了人們對演算法偏差和儲存安全的擔憂，導致相關人員在將這些工具整合到常規臨床實踐中之前持謹慎態度。

這一障礙的嚴重程度清晰地體現在醫療專業人員不願在沒有強力的保障措施的情況下全面採用這些技術。身為患者照護的主要安全隔離網閘，醫師們仍然對缺乏嚴格資料保護保障的工具保持警惕。美國醫學會 (AMA) 2024 年的一項調查發現，87% 的醫生認為資料隱私保障是採用新型人工智慧醫療解決方案的關鍵要求。如果沒有此類保障，市場將難以將技術能力轉化為廣泛的臨床應用，從而限制治療覆蓋範圍和收入成長。

市場趨勢

以語音為基礎的生物標記正成為診斷領域的一股變革力量，為評估精神疾病的嚴重程度提供非侵入性、客觀的指標。與傳統的主觀調查不同，這些生物標記利用機器學習來解讀音調、音高和節奏等聲學細節，從而有可能在焦慮和憂鬱症出現臨床症狀之前，就揭示出與之相關的細微生理變化。這項創新技術正從實驗階段走向實際臨床應用，為人群健康管理提供了一個可擴展的方案。 Ellipsis Health 於 2025 年 7 月展示了這項技術的實用性。他們的研究「里程碑式研究檢驗了語音人工智慧在真實臨床實踐中檢測憂鬱症的有效性」表明，一項基於人工智慧的分析對 2007 個病例管理電話進行了分析，其結果與標準 PHQ-8 評估的一致性相關係數達到了 0.54。

同時，分散式精神臨床試驗（DCT）的蓬勃發展正在革新藥物研發，它利用遠端監測工具克服了人口統計和地理障礙。分散式框架最大限度地減少了現場訪視的需求，顯著提高了參與者的多樣性，從而能夠在更具代表性的患者群體中評估精神治療效果。這種方法對於將試驗結果推廣到更廣泛的人群至關重要，而這些人群在精神健康研究中往往代表性不足。 FierceBiotech 於 2025 年 1 月證實了該模式的整體性。基於塔夫茨藥物研發研究中心的數據，《利用分散式試驗提高病患多樣性：一項研究》指出，分散式模式將亞裔參與者的比例提高到 20.9%，而傳統模式下這一比例為 14.2%。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球精神醫學數位生物標記市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（穿戴式裝置、行動應用程式、感測器、其他）
  • 臨床實踐（用於診斷的精神科數位生物標記、用於監測的精神科數位生物標記、用於預測/預後的精神科數位生物標記、其他）
  • 按最終用戶（醫療保健公司、醫療保健提供者、支付方、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美精神病學數位生物標記市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲精神病學數位生物標記市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區精神病學數位生物標記市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲精神病學數位生物標記市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美精神病學數位生物標記市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球精神病學數位生物標記市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Koneksa Health Inc
• Biogen, Inc
• Empatica Inc
• VivoSense, Inc
• IXICO plc
• Huma Therapeutics Limited
• Sonde Health, Inc
• Clario

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Psychiatric Digital Biomarkers Market is projected to expand significantly, rising from USD 786.98 Million in 2025 to USD 2262.02 Million by 2031, reflecting a CAGR of 19.24%. These biomarkers involve objective, quantifiable physiological and behavioral data harvested through digital platforms like smartphones and wearable devices, aimed at detecting and monitoring mental health conditions. A primary growth engine is the urgent requirement for objective clinical assessment tools to augment subjective patient reporting, alongside the growing necessity for scalable remote monitoring in both patient care and drug development. According to the Digital Medicine Society in 2024, the inclusion of digital endpoints in Phase 3 clinical trials has been shown to boost expected net present value by up to $40 million per indication, underscoring the lucrative return on investment for pharmaceutical developers embracing these innovations.

Despite these strong commercial drivers, the market encounters substantial obstacles related to data privacy and regulatory intricacies. The gathering of highly sensitive mental health information triggers serious ethical issues concerning patient consent, data security, and the risk of algorithmic bias. These privacy challenges contribute to a disjointed regulatory environment that makes global compliance difficult and threatens to diminish patient trust, ultimately slowing the broad clinical adoption of these digital solutions.

Market Driver

The escalating prevalence of mental health disorders serves as a foundational force propelling the uptake of psychiatric digital biomarkers, shifting the focus from purely subjective reporting to objective, scalable diagnostic measures. As global burdens of anxiety and depression rise, healthcare systems depend increasingly on digital phenotyping to manage extensive patient populations efficiently. This critical need is highlighted by recent statistics; the Substance Abuse and Mental Health Services Administration reported in July 2024, within the '2023 National Survey on Drug Use and Health', that roughly 22.8% of adults in the United States experienced a mental illness in the preceding year. This growing disease burden necessitates digital tools that facilitate continuous remote monitoring to identify behavioral or physiological deviations early for prompt intervention.

Concurrently, a wave of investment in digital mental health technologies is rapidly enhancing the clinical validation and technical sophistication of these biomarkers. Venture firms and pharmaceutical companies are aggressively funding precision psychiatry platforms that utilize machine learning for patient stratification and treatment optimization. A key example of this market confidence appeared when Alto Neuroscience raised approximately $128.6 million in its February 2024 Initial Public Offering, as reported in 'Alto Neuroscience Announces Pricing of Initial Public Offering', to fund biomarker-defined psychiatric treatments. This financial drive is bolstered by regulatory achievements in consumer hardware; for instance, Samsung Electronics received FDA De Novo authorization in 2024 for a sleep apnea detection feature, confirming the clinical applicability of consumer-grade sensors for neurological and psychiatric monitoring.

Market Challenge

Data privacy concerns and regulatory complexities exert significant negative pressure on the Global Psychiatric Digital Biomarkers Market by undermining the essential trust needed for clinical implementation. Since these biomarkers depend on the persistent tracking of deeply sensitive behavioral and physiological data, any ambiguity regarding data governance fosters considerable resistance among providers and patients alike. Fragmented regulatory frameworks across various jurisdictions lead to heightened compliance costs and delayed market access, effectively hindering the rollout of scalable remote monitoring technologies. This absence of unified, clear standards intensifies worries about algorithmic bias and storage security, causing stakeholders to pause before integrating these tools into routine care.

The scale of this impediment is clearly reflected in the hesitation of healthcare professionals to fully adopt these technologies without strong safeguards. Physicians, acting as the principal gatekeepers of patient care, remain cautious of tools that lack rigorous data protection guarantees. According to the American Medical Association in 2024, 87% of physicians cited data privacy assurances as a critical requirement for adopting new AI-enabled healthcare solutions. Without such guarantees, the market faces difficulty in translating its technical capabilities into widespread clinical usage, thereby restricting therapeutic reach and revenue expansion.

Market Trends

Vocal and speech-based biomarkers are emerging as a transformative force in diagnostics, offering non-invasive, objective metrics for assessing mental health severity. Unlike conventional subjective surveys, these biomarkers employ machine learning to interpret acoustic details like tone, pitch, and rhythm, which can unveil subtle physiological shifts linked to anxiety and depression before they become clinically visible. This innovation is transitioning from experimental phases to practical clinical use, providing scalable options for population health management. The operational readiness of this technology was demonstrated in July 2025 by Ellipsis Health; their study, 'Breakthrough study validates voice AI for real-world depression detection in healthcare', showed that AI-driven analysis of 2,007 case management calls achieved a concordance correlation coefficient of 0.54 against standard PHQ-8 assessments.

Simultaneously, the proliferation of Decentralized Psychiatric Clinical Trials (DCTs) is revolutionizing drug development by utilizing remote monitoring tools to surmount demographic and geographic hurdles. By minimizing the need for physical site visits, decentralized frameworks notably improve participant diversity, ensuring psychiatric treatments are evaluated across a more representative patient base. This approach is vital for applying trial findings to broader demographic groups that are frequently underrepresented in mental health studies. The efficacy of this model in promoting inclusivity was confirmed by FierceBiotech in January 2025; reporting on data from the Tufts Center for the Study of Drug Development in 'Using decentralized trials improves patient diversity: study', it was noted that decentralized formats raised Asian participant representation to 20.9%, compared to 14.2% in traditional models.

Key Market Players

• Koneksa Health Inc
• Biogen, Inc
• Empatica Inc
• VivoSense, Inc
• IXICO plc
• Huma Therapeutics Limited
• Sonde Health, Inc
• Clario

Report Scope

In this report, the Global Psychiatric Digital Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psychiatric Digital Biomarkers Market, By Type

• Wearable
• Mobile based Applications
• Sensors
• Others

Psychiatric Digital Biomarkers Market, By Clinical Practice

• Diagnostic Psychiatric Digital Biomarkers
• Monitoring Psychiatric Digital Biomarkers
• Predictive and Prognostic Psychiatric Digital Biomarkers
• Other

Psychiatric Digital Biomarkers Market, By End User

• Healthcare companies
• Healthcare Providers
• Payers
• Others

Psychiatric Digital Biomarkers Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psychiatric Digital Biomarkers Market.

Available Customizations:

Global Psychiatric Digital Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psychiatric Digital Biomarkers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Wearable, Mobile based Applications, Sensors, Others)
  • 5.2.2. By Clinical Practice (Diagnostic Psychiatric Digital Biomarkers, Monitoring Psychiatric Digital Biomarkers, Predictive and Prognostic Psychiatric Digital Biomarkers, Other)
  • 5.2.3. By End User (Healthcare companies, Healthcare Providers, Payers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Psychiatric Digital Biomarkers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Clinical Practice
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Psychiatric Digital Biomarkers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Clinical Practice
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Psychiatric Digital Biomarkers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Clinical Practice
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Psychiatric Digital Biomarkers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Clinical Practice
      • 6.3.3.2.3. By End User

7. Europe Psychiatric Digital Biomarkers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Clinical Practice
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Psychiatric Digital Biomarkers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Clinical Practice
      • 7.3.1.2.3. By End User
  • 7.3.2. France Psychiatric Digital Biomarkers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Clinical Practice
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Psychiatric Digital Biomarkers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Clinical Practice
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Psychiatric Digital Biomarkers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Clinical Practice
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Psychiatric Digital Biomarkers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Clinical Practice
      • 7.3.5.2.3. By End User

8. Asia Pacific Psychiatric Digital Biomarkers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Clinical Practice
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Psychiatric Digital Biomarkers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Clinical Practice
      • 8.3.1.2.3. By End User
  • 8.3.2. India Psychiatric Digital Biomarkers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Clinical Practice
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Psychiatric Digital Biomarkers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Clinical Practice
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Psychiatric Digital Biomarkers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Clinical Practice
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Psychiatric Digital Biomarkers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Clinical Practice
      • 8.3.5.2.3. By End User

9. Middle East & Africa Psychiatric Digital Biomarkers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Clinical Practice
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Psychiatric Digital Biomarkers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Clinical Practice
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Psychiatric Digital Biomarkers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Clinical Practice
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Psychiatric Digital Biomarkers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Clinical Practice
      • 9.3.3.2.3. By End User

10. South America Psychiatric Digital Biomarkers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Clinical Practice
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Psychiatric Digital Biomarkers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Clinical Practice
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Psychiatric Digital Biomarkers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Clinical Practice
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Psychiatric Digital Biomarkers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Clinical Practice
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Psychiatric Digital Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Koneksa Health Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Biogen, Inc
• 15.3. Empatica Inc
• 15.4. VivoSense, Inc
• 15.5. IXICO plc
• 15.6. Huma Therapeutics Limited
• 15.7. Sonde Health, Inc
• 15.8. Clario

16. Strategic Recommendations

17. About Us & Disclaimer